Myriad Genetics Inc (MYGN.OQ)
23 Feb 2018
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|73||2005||Independent Chairman of the Board|
|55||2015||President, Chief Executive Officer, Director|
|47||2017||President-President Assurex Health|
|85||Independent Vice Chairman of the Board|
|46||2014||Chief Financial Officer, Treasurer|
- BRIEF-Myriad Genetics Q2 Adjusted Earnings Per Share $0.31
- UPDATE 1-U.S. FDA approves expanded use of AstraZeneca cancer drug
- BRIEF-Myriad Genetics Announces Expanded Research Collaboration With AstraZeneca
- BRIEF-Myriad Genetics posts Q1 adjusted earnings per share $0.26
- BRIEF-Myriad announces GeneSight Psychotropic results from a large prospective trial in patients with major depressive disorder